Trial Profile
An Open-label, Randomized, Two-way Balanced Crossover Study to Investigate the Bioavailability of two forms of GSK1363089 in Subjects with Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Foretinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors GSK
- 21 Jun 2010 Actual patient number (12) added as reported by ClinicalTrials.gov.
- 21 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jun 2010 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.